Corporate Social Responsibility
Adhere To The Principle Of Sustainable Development To Create A Better Life
Jiankang Yuan's share repurchase and dividend distribution: Five years of repurchase of 2.7 billion yuan, releasing a long-term value signal
Published Time：
2025-05-09
Recently, to boost confidence in the capital market, Chinese regulators have rolled out a series of measures to encourage listed companies to actively return value to investors through share buybacks and cash dividends. The China Securities Regulatory Commission (CSRC) has formulated guidelines for market value management and introduced policies encouraging dividends and buybacks, actively promoting a new era of A-share market value management.
Under the guidance of the new "National Nine Articles" policy, many high-quality companies have taken action. Wind data shows that the total amount of share buybacks by Shanghai and Shenzhen A-share companies reached 90.92 billion yuan in 2023 and 165.62 billion yuan in 2024, an increase of 82%. Jiankangyuan Pharmaceutical Group (600380.SH) actively responded to the national call, continuously implementing large-scale share buybacks and stable high-proportion cash dividends, taking concrete actions to maintain company value and reward shareholders.
Cumulative buyback of 2.7 billion yuan over five years, cancellation of 218 million shares demonstrates confidence
Over the past five years, Jiankangyuan has implemented five rounds of share buybacks, investing nearly 2.7 billion yuan in total to repurchase and cancel company shares. A total of over 218 million shares have been cancelled, accounting for 11.92% of the company's total share capital. The large-scale buyback and cancellation have significantly reduced Jiankangyuan's total share capital, highlighting the company's high recognition of its long-term value and firm confidence in its future prospects. In the A-share market, Jiankangyuan has consistently ranked among the top in terms of the scale and proportion of buybacks and cancellations. Analysts point out that such a large-scale share buyback reflects, on the one hand, the management's strong confidence in the company's intrinsic value, and on the other hand, the company's willingness to use real money to protect shareholder rights and stabilize investor expectations.
Dividends increased by another 10%, releasing a stable cash flow
The 2024 annual report shows that Jiankangyuan plans to distribute a cash dividend of 2 yuan (including tax) per 10 shares, totaling 366 million yuan, a year-on-year increase of nearly 10%. In the current macroeconomic environment, it is uncommon for companies to maintain high-proportion dividends, which also indirectly shows that Jiankangyuan has a good cash flow and asset-liability structure, and a firm commitment to long-term responsibility to shareholders.
It is worth noting that since 2020, Jiankangyuan's cumulative dividend payments have exceeded 1.2 billion yuan, and together with cumulative buybacks exceeding 3.9 billion yuan, it has built a dual return system of "cash payout + share repurchase" rarely seen in the A-share pharmaceutical sector.
The industry logic behind shareholder returns
The pharmaceutical industry is currently in a stage of "dual squeeze" of valuation compression and intensified competition. The logic of relying on high valuations and high growth in the past is gradually giving way to the core values of stable operation, sustained profitability, and improved capital efficiency.
Under this industry trend, Jiankangyuan has demonstrated a "steady and progressive" model through a series of substantive actions: on the one hand, relying on its core businesses in respiratory and anti-infective areas to stabilize its performance base, and on the other hand, continuously improving shareholder returns and strengthening its valuation safety cushion through dividends and buybacks.
A capital trend indicator that transcends cycles
Industry analysts believe that Jiankangyuan's "high-return" strategy is not a temporary measure to respond to market sentiment, but part of its long-term capital planning. From the perspective of shareholder structure, the proportion of institutional holdings has increased year by year, showing that long-term funds recognize its fundamentals and capital discipline.
More importantly, with the gradual realization of the company's innovative drug business and the accelerated increase in the volume of respiratory products, this capital structure, with "stability + elasticity" as its core, will provide strong support for the next round of valuation recovery.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.